A. Conley

R. Gonzalez, M. Bui, J. Zager, 2013, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels

Wei-Lien Wang, A. Lazar, L. Rhines, 2022, Frontiers in Oncology.

The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis

Wei-Lien Wang, A. Lazar, R. Benjamin, 2013, Clinical Sarcoma Research.

Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study

E. Sturgis, A. Lazar, R. Benjamin, 2022, Cancer.

Disseminated Coccidioidomycosis Following COVID-19 Mimicking Metastatic Thoracic Relapse of Well-Differentiated Liposarcoma: A Case Report

E. Keung, N. Maloney, A. Conley, 2021, Frontiers in Medicine.

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.

S. Kesari, T. Reid, L. Nabell, 2022, Future oncology.

Cause of death in patients with lower‐risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Cancer.

Cause of death in patients with lower-risk myelodysplastic syndrome (MDS)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.

P. Hwu, Wei-Lien Wang, A. Lazar, 2022, The Lancet. Oncology.

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

A. Drilon, G. Demetri, M. Ahn, 2021, ESMO Open.

The immune landscape of undifferentiated pleomorphic sarcoma

J. Wargo, E. Keung, K. Wani, 2022, Frontiers in Oncology.

Retrospective evaluation of the role of gemcitabine‐docetaxel in well‐differentiated and dedifferentiated liposarcoma

E. Keung, C. Roland, B. Feig, 2022, Cancer medicine.

The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope

J. Roszik, Shreyaskumar R Patel, V. Subbiah, 2017, Current Oncology Reports.

Extraskeletal Myxoid Chondrosarcomas

Wei-Lien Wang, A. Lazar, C. Roland, 2019, American journal of clinical oncology.

Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor

G. Demetri, A. Conley, V. Trinh, 2019, Journal of Immunotherapy for Cancer.

Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor.

D. Reed, S. Attia, A. Conley, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot

T. Reid, B. Oronsky, B. Gastman, 2022, Cancers.

Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma

Wei-Lien Wang, A. Lazar, L. Rhines, 2022, Journal of immunotherapy.

Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy—A Retrospective Chart Extract-Based Approach

C. Keir, E. Wu, A. Guérin, 2012, Journal of Gastrointestinal Cancer.

Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology

A. Lazar, B. Amini, V. Lewis, 2018, Current Oncology Reports.

Clear Cell Chondrosarcoma: Clinical Characteristics and Outcomes in 15 Patients

P. Lin, V. Lewis, R. Satcher, 2020, Sarcoma.

A tool for discovering drug sensitivity and gene expression associations in cancer cells

J. Roszik, E. Grimm, Yong Qin, 2017, PloS one.

Targeted Therapy in Solid Tumors: Sarcomas

Shreyaskumar R Patel, V. Ravi, A. Conley, 2015 .

Molecular Pathology of Bone and Soft Tissue Neoplasms and Potential Targets for Novel Therapy

M. Bui, A. Conley, E. Henderson-Jackson, 2014 .

Epidemiology and therapies for metastatic sarcoma

E. Amankwah, D. Reed, A. Conley, 2013, Clinical epidemiology.

MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma

A. Lazar, P. Hwu, C. Roland, 2019, Cancers.

Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor

Angshumoy Roy, L. Rhines, B. Amini, 2020, Clinical Sarcoma Research.

Immuno-genomic landscape of osteosarcoma

P. A. Futreal, Hannah C. Beird, G. Mills, 2020, Nature Communications.

Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials

K. Hess, F. Meric-Bernstam, R. Kurzrock, 2016, Oncotarget.

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas

P. Stephens, V. Miller, F. Meric-Bernstam, 2017, Oncotarget.

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers

Mary F. McGuire, R. Murthy, R. Benjamin, 2018, Clinical Cancer Research.

Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations

Hannah C. Beird, F. Meric-Bernstam, P. Hwu, 2018, Oncotarget.

Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets

J. Roszik, V. Subbiah, V. Ravi, 2019, Cancers.

Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience

V. Sondak, R. Gonzalez, M. Bui, 2015, PloS one.

Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities

Vivek Subbiah, V. Subbiah, Denis L Fontes Jardim, 2013, Orphanet Journal of Rare Diseases.

Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard

A. Lazar, C. Roland, B. Feig, 2017, Scientific Reports.

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

J. Foster, J. Doroshow, A. Chen, 2021 .

Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma

L. Mustachio, J. Roszik, V. Subbiah, 2021, Cancers.

Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients

R. Benjamin, B. Amini, Shreyaskumar R Patel, 2017, Scientific Reports.

Treatment Patterns, Prescribing Decision Drivers, and Predictors of Complete Response Following Disease Recurrence in Gastrointestinal Stromal Tumor Patients—a Chart Extract-Based Approach

C. Keir, E. Wu, A. Guérin, 2014, Journal of Gastrointestinal Cancer.

Synergistic induction of apoptosis by the Bcl‐2 inhibitor ABT‐737 and imatinib mesylate in gastrointestinal stromal tumor cells

L. Nolden, J. Trent, A. Duensing, 2011, Molecular oncology.

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor

A. Lazar, Wei-Lien Wang, S. George, 2010, Cancer Chemotherapy and Pharmacology.

Outcomes of systemic therapy in metastatic phyllodes tumor of the breast

C. Roland, R. Benjamin, J. Ludwig, 2021, Breast Cancer Research and Treatment.

The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes

A. Lazar, N. Fleming, Wei-Lien Wang, 2018, International Journal of Gynecologic Cancer.

Treatment of Recurrent or Metastatic Uterine Adenosarcoma

N. Fleming, V. Ravi, Heather Y. Lin, 2017, Sarcoma.

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

K. Hess, F. Meric-Bernstam, A. Ryan, 2021, ESMO open.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF‐mutated melanoma and other advanced malignancies

F. Meric-Bernstam, S. Patel, R. Kurzrock, 2018, Cancer.

Recent progress in the genomics of soft tissue sarcomas

Wei Zhang, J. Trent, A. Conley, 2008, Current opinion in oncology.

Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.

V. Gopalakrishnan, A. Lazar, R. Benjamin, 2017, The oncologist.

Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.

C. Keir, E. Wu, A. Macalalad, 2015, JAMA oncology.

A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis.

R. Gonzalez, S. G. de la Fuente, J. Zager, 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours.

B. Hobbs, P. Fox, A. Lazar, 2016, The British journal of radiology.

Predictors of survival after resection of primary sarcomas of the chest wall—A large, single‐institution series

J. Roth, S. Swisher, R. Mehran, 2018, Journal of surgical oncology.

Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

E. Sausville, A. Conley, M. Nathenson, 2018, The oncologist.

PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma

P. Bhosale, C. Roland, B. Feig, 2020, Sarcoma.

High-Throughput Architecture for Discovering Combination Cancer Therapeutics

Jason Roszik, Vivek Subbiah, Yong Qin, 2018, JCO clinical cancer informatics.

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

F. Meric-Bernstam, R. Benjamin, A. Naing, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications.

B. V. Van Tine, J. Roszik, V. Subbiah, 2021, Current problems in cancer.

Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study

H. Macapinlac, D. Hong, K. Kairemo, 2020, Diagnostics.

Chemosaturation with Percutaneous Hepatic Perfusion for Unresectable Isolated Hepatic Metastases from Sarcoma

R. Gonzalez, Junsung Choi, J. Zager, 2012, CardioVascular and Interventional Radiology.

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes

P. Hwu, A. Lazar, C. Roland, 2017, Clinical Sarcoma Research.

Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies

Robert E. Brown, A. Lazar, A. Naing, 2020, Molecular Cancer Therapeutics.

Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).

J. Brugarolas, F. Cattaruzza, J. Zalevsky, 2019, Journal of Clinical Oncology.

Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosafamide (AI): Randomized cross-over study.

R. Benjamin, Shreyaskumar R Patel, V. Ravi, 2014 .

Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma.

P. Rutkowski, H. Gelderblom, Shreyaskumar R Patel, 2018, The oncologist.

Defining the chemotherapy (CT) response in well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) of the retroperitoneum (RP): A tertiary referral cancer center experience.

R. Benjamin, J. Ludwig, Shreyaskumar R Patel, 2014 .

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

F. Meric-Bernstam, A. Lazar, C. Roland, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer

N. Ibrahim, D. Booser, D. Tripathy, 2023, Cancer.

Neoadjuvant administration of radiation therapy and intratumoral autologous dendritic cells in patients with localized high-risk soft tissue sarcomas.

M. Bui, D. Gabrilovich, D. Indelicato, 2014 .

A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.

I. Wistuba, A. Lazar, P. Hwu, 2020 .

Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications.

A. Protopopov, P. Stephens, V. Miller, 2014 .

The immune microenvironment of uterine adenosarcomas

A. Lazar, Wei-Lien Wang, V. Ravi, 2020, Clinical Sarcoma Research.

A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

P. Thall, R. Benjamin, J. Ludwig, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of chemotherapy in advanced hemangiopericyoma/solitary fibrous tumor.

A. Lazar, R. Benjamin, D. Lev, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for uterine adenosarcoma: a review

A. Conley, M. Nathenson, 2018, Expert review of anticancer therapy.

539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study

A. Drilon, S. Ou, M. Ahn, 2020 .

Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion

R. Benjamin, Shreyaskumar R Patel, V. Ravi, 2017, Sarcoma.

Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard

A. Lazar, C. Roland, B. Feig, 2017, Scientific Reports.

Impact of underestimation of risk on treatment duration and recurrence in GIST patients.

C. Keir, E. Wu, A. Macalalad, 2014 .

A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes.

A. Lazar, C. Roland, L. Solis, 2022, Journal of Clinical Oncology.

Modulation of YAP/ TAZ by statins to improve survival in epithelioid hemangioendothelioma (EHE).

S. Yalamanchili, R. Benjamin, Shreyaskumar R Patel, 2020 .

Pilot study of NKTR214 and nivolumab in patients with sarcomas.

Narasimhan P. Agaram, L. Qin, J. Erinjeri, 2019, Journal of Clinical Oncology.

A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.

H. Tawbi, E. Keung, E. Burton, 2024, Nature cancer.

Atezolizumab for Advanced Alveolar Soft Part Sarcoma.

J. Doroshow, M. Burgess, B. V. Van Tine, 2023, The New England journal of medicine.

Surgical Management of Primary Skull Base Osteosarcomas: Impact of Margin Status and Patterns of Relapse.

S. Raza, E. Hanna, Wei-Lien Wang, 2019, Neurosurgery.

Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma

Hannah C. Beird, K. Wani, Wei-Lien Wang, 2023, HGG advances.

Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?

J. Ludwig, V. Ravi, N. Somaiah, 2024, Cancers.

A randomized, placebo-controlled, phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma.

Robin L. Jones, J. Blay, H. Gelderblom, 2022, Journal of Clinical Oncology.

Expression and clinical correlations of PRAME in sarcoma subtypes.

A. Lazar, P. Hwu, A. Futreal, 2016 .

The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.

Shreyaskumar R Patel, S. Raza, A. Conley, 2024, Neurosurgical focus.